Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and prebiotics effective in preventing adverse effects associated with the use of proton-pump inhibitors
The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome.
1. A pharmaceutical composition, comprising:
an absorption ready vitamin;
an absorption ready mineral;
a probiotic comprising a 50:50 mixture of Lactobacillus acidophilus and Lactobacillus casei ; and
a prebiotic comprising a 50:50 mixture of FOS (fructooligosaccharides) and inulin.
2. The pharmaceutical composition of claim 1 , wherein the vitamin is selected from the group consisting of vitamin D, vitamin K, Vitamin B12, and mixtures thereof.
3. The pharmaceutical composition of claim 2 , wherein vitamin D is selected from the group consisting of calciferol, cholecalciferol, ergocalciferol, and mixtures thereof.
4. The pharmaceutical composition of claim 2 , wherein the vitamin K is selected from the group comprising of menaquinone-7, menaquinone-4, and mixtures thereof.
5. The pharmaceutical composition of claim 2 , wherein the vitamin B12 is selected from the group comprising of methylcobalamin, cyanocobalamin, hydroxocobalamin, and mixtures thereof.
6. The pharmaceutical composition of claim 1 , wherein the absorption ready mineral is selected from the group consisting of a calcium salt, an iron salt, and mixtures thereof.
7. The pharmaceutical composition of claim 6 , wherein the calcium salt is calcium citrate malate.
8. The pharmaceutical composition of claim 6 , wherein the iron salt is ferrous bisglycinate.
9. The pharmaceutical composition of claim 1 , further comprising a probiotic selected from the group comprising of Bacillus clausi, Bacillus coagulans, Lactobacillus brevis, Lactobacillus vulgaricus, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus lactis, Lactobacillus reuteri, Bifidobacterium bifidum, Streptococcus thermophiles, Enterococcus faecium , and mixtures thereof.
10. The pharmaceutical composition of claim 1 , wherein:
a first vitamin is present in an amount of 5 μg to 25 μg, equivalent to 200 IU to 1,000 IU;
a second vitamin is present in an amount of 25 μg to 200 μg;
a third vitamin is present in an amount of 6 μg to 250 μg;
a calcium salt present in an amount of 837 mg to 4,183 mg, equivalent to 200 mg to 1,000 mg of elemental calcium;
an iron salt in an amount of 30 mg to 450 mg, equivalent to 6 mg to 90 mg of elemental iron;
a first probiotic in a concentration of 1 billion CFU to 10 billion CFU;
a second probiotic in a concentration of 1 billion CFU to 10 billion CFU;
a first prebiotic; and
a second prebiotic.
11. The pharmaceutical composition of claim 10 , wherein:
the first vitamin is vitamin D3, as cholecalciferol, present in an amount of 10 to 20 μg, equivalent to 400 IU to 800 IU;
the second vitamin is vitamin K2, as menaquinone-7, present in an amount of 50 μg to 100 μg;
the third vitamin is vitamin B12, as methylcobalamin, in an amount of 50 μg to 100 μg;
calcium is present as calcium citrate malate, present in an amount of 1,046 mg to 2,092 mg, equivalent to 250 mg to 500 mg of elemental calcium;
iron is present as ferrous bisglycinate, present in an amount of 90 mg to 225 mg, equivalent to 18 mg to 45 mg of elemental iron;
the first probiotic is Lactobacillus acidophilus , present in an amount of 2.5 billion CFU to 7.5 billion CFU;
the second probiotic is Lactobacillus casei , present in an amount of 2.5 billion CFU to 7.5 billion CFU;
the first prebiotic FOS (fructooligosaccharides), in an amount of 25 mg to 500 mg FOS (fructooligosaccharides); and
the second prebiotic is an inulin in an amount of between 25 mg to 500 mg.
12. The pharmaceutical composition of claim 11 , wherein the first prebiotic FOS (fructooligosaccharides) is present in an amount of 50 mg to 200 mg.
13. The pharmaceutical composition of claim 1 , comprising an excipient.
14. The pharmaceutical composition of claim 13 , wherein the excipient is selected from the group consisting of a diluent, a disintegrant, a glidant, a lubricant, and mixtures thereof.
15. The pharmaceutical composition of claim 14 , further comprising:
a diluent in a concentration of 5% to 20% of the total weight of the preparation;
a disintegrant in a concentration of 0.5% to 5% of the total weight of the preparation;
a glidant in a concentration of 0.5% to 5% of the total weight of the preparation; and
a lubricant in a concentration of 0.5% to 3% of the total weight of the preparation.
16. A method of treatment to avoid adverse effects associated with the use of proton-pump inhibitors, comprising: oral administration of the pharmaceutical composition of claim 1 .
17. The method of treatment to avoid adverse effects associated with the use of proton-pump inhibitors of claim 16 , wherein: the absorption ready vitamin includes cholecalciferol from 10 μg and 20 μg, equivalent to 400 IU and 800 IU of vitamin D3; menaquinone-7 from 50 μg to 100 μg; methylcobalamin from 50 μg to 100 μg;
the absorption ready mineral includes calcium citrate malate from 1,046 mg to 2,092 mg, equivalent to 250 mg to 500 mg of elemental calcium; magnesium oxide from 166 mg to 664 mg, equivalent to 100 mg to 400 mg of elemental magnesium; ferrous bisglycinate from 90 mg to 225 mg, equivalent to 18 mg to 45 mg of elemental iron;
the probiotic includes Lactobacillus acidophilus from 2.5 billion CFU to 7.5 billion CFU and Lactobacillus casei from 2.5 billion CFU to 7.5 billion CFU; and the prebiotic includes FOS (fructooligosaccharides) from 50 mg to 200 mg and inulin from 50 mg to 200 mg.
18. The method of treatment of claim 16 , wherein the pharmaceutical composition is administered from 4 to 6 hours after the first daily administration of the proton-pump inhibitor.
19. The method of claim 18 , wherein the pharmaceutical composition is administered in two capsules or tablets, each one containing half the total daily dose required.
20. A method of preparation of a pharmaceutical composition that prevents adverse effects associated with the use of proton-pump inhibitors, comprising:
sifting Vitamins D3, K2, and B12 and colloidal silicon dioxide through a #100 mesh;
geometrically diluting the vitamins D3, K2 and B12 in colloidal silicon dioxide and mixing for 5 minutes at each dilution to obtain a geometrically diluted pre-mix;
sifting microcrystalline cellulose through a #30 mesh;
geometrically diluting the obtained pre-mix in microcrystalline cellulose, mixing for 5 minutes at each dilution to obtain a pre-mix which is added to a mixer and mixed for 10 minutes;
separately, Lactobacillus acidophilus, Lactobacillus casei , FOS (fructooligosaccharides), and inulin are mixed for 5 minutes after being previously sifted through a #30 mesh to obtain a pre-mix which is added to a mixer and mixed for 10 minutes;
separately, iron bisglycinate, magnesium oxide, and sodium croscarmellose are mixed for 5 minutes after being previously sifted through a #30 mesh to obtain a pre-mix which is added to a mixer and mixed for 10 minutes;
calcium citrate malate is placed in a “V” mixer after being previously sifted through a #20 mesh;
vegetable magnesium stearate, previously sifted through a #60 mesh, is added to the mixer and mixed for 3 minutes, which yields a pharmaceutical composition comprising;
an absorption ready vitamin;
an absorption ready mineral;
a probiotic comprising a 50:50 mixture of Lactobacillus acidophilus and Lactobacillus casei ; and
a prebiotic comprising a 50:50 mixture of FOS (fructooligosaccharides) and inulin.
21. The method of claim 20 , wherein a “#00” capsule is filled with an average weight of 850 mg of the pharmaceutical composition.
22. A pharmaceutical composition, comprising:
an absorption ready vitamin; wherein
a first vitamin is present in an amount of 5 μg to 25 μg, equivalent to 200 IU to 1,000 IU;
a second vitamin is present in an amount of 25 μg to 200 μg;
a third vitamin is present in an amount of 6 μg to 250 μg;
an absorption ready mineral; wherein said absorption ready mineral is at least one of a calcium salt or an iron salt and wherein
the calcium salt present in an amount of 837 mg to 4,183 mg, equivalent to 200 mg to 1,000 mg of elemental calcium;
the iron salt in an amount of 30 mg to 450 mg, equivalent to 6 mg to 90 mg of elemental iron;
a first probiotic in a concentration of 1 billion CFU to 10 billion CFU;
a second probiotic in a concentration of 1 billion CFU to 10 billion CFU; and
a prebiotic.
23. The pharmaceutical composition of claim 22 , wherein:
the first vitamin is vitamin D3, as cholecalciferol, present in an amount of 10 μg to 20 μg, equivalent to 400 IU to 800 IU;
the second vitamin is vitamin K2, as menaquinone-7, present in an amount of 50 μg to 100 μg;
the third vitamin is vitamin B12, as methylcobalamin, in an amount of 50 μg to 100 μg;
calcium is present as calcium citrate malate, present in an amount of 1,046 mg to 2,092 mg, equivalent to 250 mg to 500 mg of elemental calcium;
iron is present as ferrous bisglycinate, present in an amount of 90 mg to 225 mg, equivalent to 18 mg to 45 mg of elemental iron;
the first probiotic is Lactobacillus acidophilus , present in an amount of 2.5 billion CFU to 7.5 billion CFU;
the second probiotic is Lactobacillus casei , present in an amount of 2.5 billion CFU to 7.5 billion CFU;
the first prebiotic FOS (fructooligosaccharides), in an amount of 25 mg to 500 mg FOS (fructooligosaccharides), present in an amount of 50 mg to 200 mg; and
the second prebiotic is an inulin in an amount of between 25 mg to 500 mg.